Ceribell (CBLL) Cash from Financing Activities (2023 - 2026)
Ceribell's (CBLL) quarterly Cash from Financing Activities came in at $1.6 million in Q1 2026, up 81500.0% YoY from N/an in Q1 2025, and up 16.32% on a QoQ basis from $1.4 million in Q4 2025.
Ceribell (CBLL) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Ceribell (CBLL) has 4 years of Cash from Financing Activities data on file, last reported at $1.6 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 81500.0% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (down 96.46% YoY) and the FY2025 annual result came in at $5.1 million, down 97.43% from the prior year.
- Cash from Financing Activities rose to $1.6 million in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $190.7 million in Q4 2024 to a low of -$3.5 million in Q4 2023.
- A 4-year average of $20.0 million and a median of $1.5 million in 2025 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 100400.0% in 2025, down 99.97% in 2025.
- Tracing CBLL's Cash from Financing Activities over 4 years: stood at -$3.5 million in 2023, then jumped by 5609.19% to $190.7 million in 2024, then plunged by 99.26% to $1.4 million in 2025, then advanced by 16.32% to $1.6 million in 2026.
- The last three Cash from Financing Activities figures came in at $1.6 million (Q1 2026), $1.4 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.95 Bn | 193.35 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 128.10 Bn | 124.63 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.91 Bn | 109.69 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 73.43 Bn | 72.89 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.91 Bn | 47.66 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.52 Bn | 32.58 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.94 Bn | 31.83 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.14 Bn | 22.66 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Ceribell | 925.32 Mn | 796.06 Mn | 25.94 Mn | 880,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 880,000.00 |
| Jun 30, 2026 | 880,000.00 |
| Mar 31, 2026 | 1.63 Mn |
| Mar 31, 2026 | 1.63 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 190.73 Mn |
| Dec 31, 2024 | 190.73 Mn |
| Sep 30, 2024 | -1.89 Mn |
| Sep 30, 2024 | -1.89 Mn |
| Jun 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | 7.68 Mn |
| Mar 31, 2024 | 7.68 Mn |